Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent Encorafenib and Binimetinib in Metastatic Melanoma
NCT02263898Phase 2Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jan 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib and binimetinib in melanoma, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Progression Free Survival rate at 1 year. Planned start Jan 2015; status: withdrawn.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02263898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02263898.